Business InMed Pharma rolls out rare cannabinoid via BayMedica D9-THCV one of many in company cannabinoid portfolio set to diversify and expand in coming years Rowan DunneJune 13, 2022
Business InMed Pharmaceuticals reports net loss of US$10.2M The firm says expenses will increase as research and 'important progress' continues Kathryn TindaleSeptember 24, 2021